Volatility Stories
Considering the 60-day investment horizon Inhibikase TherapeuticsInc is expected to generate 91.13 times more return on investment than the market. However, the company is 91.13 times more volatile than its market benchmark. It trades about 0.13 of its potential returns per unit of risk.
| over a year ago at Macroaxis By Rifka Kats |  |
GMS is generating 0.3813% of daily returns assuming volatility of 1.83% on return distribution over 60 days investment horizon. While some of us are excited about trading companies & distributors space, it makes sense to review GMS in greater detail to make a better estimate of its risk and reward. We will break down how risky is to take a position in GMS at this time. GMS's very low volatility may have no significant impact on the stock's value as we estimate GMS as currently undervalued. The real value, based on our calculations, is getting close to 70.49 per share.
| over a year ago at Macroaxis By Raphi Shpitalnik |  |
50% of stocks are less volatile than Motorcar, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. As many adventurous traders are excited about auto components space, it is only fair to go over the risk of shorting Motorcar Parts based on its current volatility spike. We will go over a few points Motorcar Parts investors should remember regarding its volatility.
| over a year ago at Macroaxis By Vlad Skutelnik |  |
63% of stocks are less volatile than Mind, and 85% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. As many adventurous traders are excited about energy equipment & services space, it is only fair to digest the risk of shorting Mind Technology based on its current volatility spike. We will cover the possibilities of Mind Technology's current volatility to continue through July.
| over a year ago at Macroaxis By Vlad Skutelnik | |
Mitek Systems is currently generating 0.237% in daily expected returns and assumes 2.161% risk (volatility on return distribution) over the 90 days horizon. Although many risk-takers are getting more into software space, some of us are not very happy with Mitek Systems' current volatility. We will go over odds for Mitek Systems to generate above-average margins next month.
| over a year ago at Macroaxis By Gabriel Shpitalnik |  |
Arrow Financial is currently does not generate positive expected returns and assumes 2.6734% risk (volatility on return distribution) over the 60 days horizon. Although many risk-takers are getting more into banks space, some of us are not very happy with Arrow Financial's current volatility. We will recap if the expected returns on Arrow Financial will justify its current volatility.
| over a year ago at Macroaxis By Aina Ster |  |
36% of stocks are less volatile than AsanaInc, and 85% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. As many adventurous traders are excited about software space, it is only fair to recap the risk of shorting AsanaInc based on its current volatility spike. We will focus on if the expected returns on AsanaInc will justify its current volatility.
| over a year ago at Macroaxis By Raphi Shpitalnik | |
Given the investment horizon of 90 days Galmed Pharmaceuticals is expected to under-perform the market. In addition to that, the company is 8.99 times more volatile than its market benchmark. It trades about -0.06 of its total potential returns per unit of risk.
| over a year ago at Macroaxis By Ellen Johnson |  |
Lifecore Biomedical is currently generating 1.8044% in daily expected returns and assumes 15.5959% risk (volatility on return distribution) over the 90 days horizon. As many old-fashioned traders are trying to avoid healthcare space, it makes sense to sum up Lifecore Biomedical a little further and try to understand its current volatility patterns. We will discuss why some retail investors are closely monitoring Lifecore Biomedical's volatility. The latest Lifecore risk factors may impact the value of the stock as we estimate Lifecore Biomedical as currently overvalued. The real value is approaching 5.75 per share.
| over a year ago at Macroaxis By Raphi Shpitalnik | |
Alpha Teknova is currently does not generate positive expected returns and assumes 5.9109% risk (volatility on return distribution) over the 90 days horizon. Although many risk-takers are getting more into healthcare space, some of us are not very happy with Alpha Teknova's current volatility. We will focus on why some insiders are closely monitoring Alpha Teknova's volatility. Alpha Teknova high volatility, while potentially profitable, can lead to more considerable losses for your portfolios.
| over a year ago at Macroaxis By Raphi Shpitalnik | |